Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 10,000 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $28.42, for a total transaction of $284,200.00. Following the sale, the chief executive officer owned 362,152 shares of the company’s stock, valued at $10,292,359.84. This trade represents a 2.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Claire Mazumdar also recently made the following trade(s):

• On Monday, April 20th, Claire Mazumdar sold 15,000 shares of Bicara Therapeutics stock. The stock was sold at an average price of $23.61, for a total transaction of $354,150.00.

Bicara Therapeutics Price Performance

Shares of BCAX stock opened at $28.10 on Wednesday. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -10.11 and a beta of -0.81. Bicara Therapeutics Inc. has a 1 year low of $9.57 and a 1 year high of $30.99. The firm has a fifty day moving average price of $23.66 and a 200-day moving average price of $20.26.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Equities research analysts expect that Bicara Therapeutics Inc. will post -3.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on BCAX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. Bank of America assumed coverage on Bicara Therapeutics in a report on Wednesday, March 25th. They set a “buy” rating and a $35.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. Citizens Jmp reiterated a “market outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Finally, Wall Street Zen raised Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.27.

Institutional Trading of Bicara Therapeutics

Hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC purchased a new position in shares of Bicara Therapeutics during the first quarter valued at about $248,000. Woodline Partners LP boosted its stake in Bicara Therapeutics by 26.5% during the first quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock valued at $4,543,000 after buying an additional 72,998 shares during the last quarter. Geode Capital Management LLC boosted its stake in Bicara Therapeutics by 36.8% during the second quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock valued at $6,248,000 after buying an additional 180,833 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Bicara Therapeutics by 26.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock valued at $255,000 after buying an additional 5,664 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.